Alignment Healthcare (ALHC) vs Castle Biosciences (CSTL)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Castle Biosciences (CSTL) has outperformed Alignment Healthcare (ALHC) over the past year, gaining 42.9% versus a loss of 50.8%. Over five years, CSTL leads with a -47.0% price change compared with -53.2% for ALHC. Alignment Healthcare is the larger company by market cap ($1.57 billion vs $1.05 billion), about 1.5 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ALHC | CSTL |
|---|---|---|
| Share price | $7.55 | $34.42 |
| Market cap | $1.57B | $1.05B |
| 1-day change | -13.36% | +2.11% |
| YTD return | -55.90% | -13.34% |
| 1-year return | -50.76% | +42.90% |
| 5-year return | -53.22% | -46.98% |
| P/E ratio (TTM) | 39.72 | — |
| Forward P/E | 10.27 | — |
| EPS (TTM) | $0.19 | $-0.64 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $3.95B | — |
| Revenue growth (YoY) | +46.06% | — |
| Net income (latest FY) | $-724.00K | — |
| Operating margin | 0.37% | — |
| Net margin | -0.02% | — |
| 52-week high | $25.12 | $44.28 |
| 52-week low | $6.01 | $17.72 |
| Distance from 52-week high | -69.96% | -22.27% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +172.20% | +31.06% |
| Average volume | 7.55M | 402.90K |
| Shares outstanding | 207.44M | 30.55M |
| Employees | 1,849 | 1,002 |
| Sector | Health Care | Health Care |
| Industry | Medical Specialities | Medical Specialities |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- CSTL has outperformed ALHC by 93.7 percentage points over the past year.
About Alignment Healthcare
ALHC stock →Alignment Healthcare, Inc. operates a consumer-centric healthcare platform for seniors in the United States.
Health Care · Medical Specialities · 1,849 employees
About Castle Biosciences
CSTL stock →Castle Biosciences, Inc., a molecular diagnostics company, provides test solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus (BE), atopic dermatitis (AD), and uveal melanoma. The company offers DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test that predicts the likelihood of a positive sentinel lymph node and the risk of metastasis for patients with invasive cutaneous melanoma; TissueCypher, a risk stratification spatialomics test to predict future development of high-grade dysplasia and/or esophageal cancer in patients with non-dysplastic, indefinite dysplasia, and low-grade dysplasia BE; AdvanceAD-Tx, a non-invasive GEP test which is designed to guide systemic treatment selection for patients aged 12 years and older with moderateto-severe AD; DecisionDx-SCC, a GEP test for cutaneous squamous cell carcinoma; and MyPath Melanoma, a diagnostic GEP test for use in patients with difficult-to-diagnose melanocytic lesions.
Health Care · Medical Specialities · 1,002 employees
ALHC vs CSTL FAQ
Which is bigger, Alignment Healthcare or Castle Biosciences?
Alignment Healthcare (ALHC) is larger, with a market capitalization of $1.57B compared with $1.05B for Castle Biosciences (CSTL).
Which stock has performed better over the past year, ALHC or CSTL?
CSTL returned +42.90% over the past 12 months, compared with -50.76% for ALHC (price return, excluding dividends). Past performance does not predict future results.
Are Alignment Healthcare and Castle Biosciences in the same industry?
Yes. Both are classified in the Medical Specialities industry within the Health Care sector.